Patients 0 8 0 8 O
must 9 13 9 13 O
have 14 18 14 18 O
untreated 19 28 19 28 O
AML 29 32 29 32 B-cancer
, 32 33 32 33 O
or 34 36 34 36 O
high 37 41 37 41 B-cancer
- 41 42 41 42 I-cancer
risk 42 46 42 46 I-cancer
myelodysplastic 47 62 47 62 I-cancer
syndromes 63 72 63 72 I-cancer
( 73 74 73 74 I-cancer
MDS 74 77 74 77 I-cancer
) 77 78 77 78 I-cancer
( 79 80 79 80 O
refractory 80 90 80 90 B-chronic_disease
anemia 91 97 91 97 I-chronic_disease
with 98 102 98 102 O
excess 103 109 103 109 O
blasts 110 116 110 116 O
, 116 117 116 117 O
[ 118 119 118 119 O
RAEB 119 123 119 123 B-chronic_disease
] 123 124 123 124 O
, 124 125 124 125 O
or 126 128 126 128 O
RAEB 129 133 129 133 O
in 134 136 134 136 O
transformation 137 151 137 151 O
[ 152 153 152 153 O
RAEB 153 157 153 157 O
- 157 158 157 158 O
t 158 159 158 159 O
] 159 160 159 160 O
) 160 161 160 161 O
characterized 162 175 162 175 O
by 176 178 176 178 O
t(8;21 179 185 179 185 O
) 185 186 185 186 O
, 186 187 186 187 O
inv(16 188 194 188 194 O
) 194 195 194 195 O
, 195 196 195 196 O
or 197 199 197 199 O
t(16;16 200 207 200 207 O
) 207 208 207 208 O
; 208 209 208 209 O
the 210 213 210 213 O
presence 214 222 214 222 O
of 223 225 223 225 O
additional 226 236 226 236 O
abnormalities 237 250 237 250 O
is 251 253 251 253 O
irrelevant 254 264 254 264 O

Patients 0 8 265 273 O
of 9 11 274 276 O
child 12 17 277 282 O
bearing 18 25 283 290 O
potential 26 35 291 300 O
should 36 42 301 307 O
practice 43 51 308 316 B-contraception_consent
effective 52 61 317 326 I-contraception_consent
methods 62 69 327 334 I-contraception_consent
of 70 72 335 337 I-contraception_consent
contraception 73 86 338 351 I-contraception_consent

Patients 0 8 352 360 O
with 9 13 361 365 O
organ 14 19 366 371 B-chronic_disease
dysfunction 20 31 372 383 I-chronic_disease
will 32 36 384 388 O
not 37 40 389 392 O
be 41 43 393 395 O
excluded 44 52 396 404 O
from 53 57 405 409 O
the 58 61 410 413 O
study 62 67 414 419 O

Pregnant 0 8 420 428 B-pregnancy
and 9 12 429 432 O
lactating 13 22 433 442 O
females 23 30 443 450 B-gender

Up 0 2 451 453 O
to 3 5 454 456 O
one 6 9 457 460 O
cycle 10 15 461 466 O
of 16 18 467 469 O
prior 19 24 470 475 B-treatment
induction 25 34 476 485 I-treatment
therapy 35 42 486 493 I-treatment
will 43 47 494 498 O
be 48 50 499 501 O
permitted 51 60 502 511 O
to 61 63 512 514 O
include 64 71 515 522 O
patients 72 80 523 531 O
in 81 83 532 534 O
whom 84 88 535 539 O
presence 89 97 540 548 O
of 98 100 549 551 O
good 101 105 552 556 O
- 105 106 556 557 O
risk 106 110 557 561 O
cytogenetics 111 123 562 574 O
was 124 127 575 578 O
initially 128 137 579 588 O
missed 138 144 589 595 O
; 144 145 595 596 O
if 146 148 597 599 O
the 149 152 600 603 O
patient 153 160 604 611 O
is 161 163 612 614 O
in 164 166 615 617 O
remission 167 176 618 627 O
from 177 181 628 632 O
induction 182 191 633 642 O
therapy 192 199 643 650 O
, 199 200 650 651 O
he 201 203 652 654 O
/ 203 204 654 655 O
she 204 207 655 658 O
will 208 212 659 663 O
receive 213 220 664 671 O
post 221 225 672 676 B-treatment
- 225 226 676 677 I-treatment
remission 226 235 677 686 I-treatment
therapy 236 243 687 694 I-treatment
; 243 244 694 695 O
if 245 247 696 698 O
the 248 251 699 702 O
patient 252 259 703 710 O
is 260 262 711 713 O
not 263 266 714 717 O
in 267 269 718 720 O
remission 270 279 721 730 O
then 280 284 731 735 O
he 285 287 736 738 O
/ 287 288 738 739 O
she 288 291 739 742 O
will 292 296 743 747 O
receive 297 304 748 755 O
induction 305 314 756 765 O
therapy 315 322 766 773 O

for 0 3 774 777 O
patients 4 12 778 786 O
with 13 17 787 791 O
evidence 18 26 792 800 O
of 27 29 801 803 O
organ 30 35 804 809 B-chronic_disease
dysfunction 36 47 810 821 I-chronic_disease
( 48 49 822 823 O
creatinine 49 59 823 833 B-clinical_variable
> 60 61 834 835 O
= 61 62 835 836 O
1.5 63 66 837 840 B-lower_bound
, 66 67 840 841 O
cardiac 68 75 842 849 B-clinical_variable
ejection 76 84 850 858 I-clinical_variable
fraction 85 93 859 867 I-clinical_variable
= 94 95 868 869 O
< 95 96 869 870 O
50 97 99 871 873 B-upper_bound
% 99 100 873 874 I-upper_bound
, 100 101 874 875 O
total 102 107 876 881 O
bilirubin 108 117 882 891 B-clinical_variable
> 118 119 892 893 O
= 119 120 893 894 O
2 120 121 894 895 B-lower_bound
and 122 125 896 899 O
aspartate 126 135 900 909 B-clinical_variable
aminotransferase 136 152 910 926 I-clinical_variable
[ 153 154 927 928 I-clinical_variable
AST]/alanine 154 166 928 940 I-clinical_variable
aminotransferase 167 183 941 957 I-clinical_variable
[ 184 185 958 959 I-clinical_variable
ALT 185 188 959 962 I-clinical_variable
] 188 189 962 963 I-clinical_variable
> 190 191 964 965 O
= 191 192 965 966 O
3 193 194 967 968 B-lower_bound
times 195 200 969 974 I-lower_bound
upper 201 206 975 980 I-lower_bound
limit 207 212 981 986 I-lower_bound
of 213 215 987 989 I-lower_bound
normal 216 222 990 996 I-lower_bound
[ 223 224 997 998 I-lower_bound
ULN 224 227 998 1001 I-lower_bound
] 227 228 1001 1002 I-lower_bound
) 228 229 1002 1003 I-lower_bound
, 229 230 1003 1004 O
dose 231 235 1005 1009 O
adjustments 236 247 1010 1021 O
/ 247 248 1021 1022 O
omissions 248 257 1022 1031 O
will 258 262 1032 1036 O
be 263 265 1037 1039 O
made 266 270 1040 1044 O

patients 0 8 1045 1053 O
with 9 13 1054 1058 O
Eastern 14 21 1059 1066 B-clinical_variable
Cooperative 22 33 1067 1078 I-clinical_variable
Oncology 34 42 1079 1087 I-clinical_variable
Group 43 48 1088 1093 I-clinical_variable
( 49 50 1094 1095 I-clinical_variable
ECOG 50 54 1095 1099 I-clinical_variable
) 54 55 1099 1100 I-clinical_variable
performance 56 67 1101 1112 I-clinical_variable
status 68 74 1113 1119 I-clinical_variable
> 75 76 1120 1121 O
= 76 77 1121 1122 O
to 78 80 1123 1125 O
3 81 82 1126 1127 B-lower_bound
the 83 86 1128 1131 O
dosing 87 93 1132 1138 O
schedule 94 102 1139 1147 O
will 103 107 1148 1152 O
be 108 110 1153 1155 O
discussed 111 120 1156 1165 O
with 121 125 1166 1170 O
study 126 131 1171 1176 O
chairman 132 140 1177 1185 O

